HCPCS Level II code J9326 describes the medication administration unit for telisotuzumab vedotin-tllv, billed per 1 mg of the injectable oncology drug; the service represents dispensing and preparation of the intravenous antineoplastic agent typically provided in oncology infusion centers or hospital outpatient infusion clinics as part of systemic cancer therapy.

For related coverage guidance, see recent payer policy updates: Epithelial Cell Cytology in Breast Cancer Risk Assessment, Antibody-Drug Conjugates, Chemotherapy Observation or Inpatient Hospitalization (for New Mexico Only).